# Official Clinical Practice Guidelines for Community-Acquired Pneumonia (2025 Update): Study Guide This study guide provides a comprehensive overview of the 2025 updates to the American Thoracic Society (ATS) clinical practice guidelines regarding the diagnosis and management of community-acquired pneumonia (CAP) in immunocompetent adults. ## Core Recommendations Summary The following table summarizes the four primary clinical questions addressed in the 2025 update, the strength of the recommendations, and the quality of evidence supporting them. | Clinical Question | Recommendation | Strength | Evidence Quality | | :--- | :--- | :--- | :--- | | **1. Lung Ultrasound (LUS)** | Acceptable diagnostic alternative to chest radiography where expertise exists. | Conditional | Low | | **2. Viral + Outpatients (No Comorbidities)** | Suggest **not** prescribing empiric antibiotics. | Conditional | Very Low | | **3. Viral + Outpatients (With Comorbidities)** | Suggest prescribing empiric antibiotics. | Conditional | Very Low | | **4. Viral + Inpatients (Nonsevere & Severe)** | Suggest prescribing empiric antibiotics. | Conditional* | Very Low | | **5. Antibiotic Duration (Outpatients/Nonsevere)** | Suggest < 5 days (minimum 3 days) if clinically stable. | Conditional | Low | | **6. Antibiotic Duration (Severe CAP)** | Suggest 5 or more days rather than < 5 days. | Strong | Low | | **7. Corticosteroids (Nonsevere Inpatients)** | Recommend **against** systemic corticosteroids. | Strong | Low | | **8. Corticosteroids (Severe Inpatients)** | Suggest systemic corticosteroids (excluding influenza). | Conditional | Low | *\*The recommendation for severe CAP inpatients was unanimous (100% vote) despite the low quality of evidence.* --- ## Key Concepts and Rationale ### Diagnosis: Lung Ultrasound (LUS) The standard diagnosis of CAP requires clinical signs and symptoms plus imaging confirmation of alveolar inflammation. While chest radiography is traditional, it is less accurate than CT scans. LUS has emerged as a portable, accurate alternative. * **Accuracy:** Meta-analysis indicates LUS has a median sensitivity of 95% compared to 70% for chest radiography. * **Expertise Requirements:** Use of LUS requires formal training in image acquisition, a standardized imaging protocol (evaluating anterior, lateral, and posterior chest walls), and a retrievable image archive. * **Limitations:** LUS may be hindered by patient factors such as obesity, drains, scars, or wounds. ### Empiric Antibacterial Therapy with Positive Viral Testing Clinicians must weigh the risk of missed bacterial-viral coinfection against the risks of unnecessary antibiotic use (e.g., *C. difficile*, resistance). * **Coinfection Risks:** Historical data from influenza pandemics show that over 90% of deaths involved bacterial coinfection (e.g., *S. pneumoniae*, *S. aureus*). * **Outpatients:** For healthy outpatients, the risk of missing a bacterial infection is deemed low enough to suggest withholding antibiotics. For those with comorbidities (chronic lung disease, alcoholism, neoplastic disease), antibiotics are suggested due to higher risks of poor outcomes. * **Inpatients:** Antibiotics are suggested for all inpatients due to the high mortality associated with delayed treatment in hospitalized settings. ### Antibiotic Duration Modern management aims to reduce bacterial load while minimizing microbiome disruption. * **Effective Duration:** This refers to the therapeutic life of the drug. For example, because azithromycin has a long half-life, a 1-day dose may be "effectively" a 4-day duration. * **Clinical Stability:** Short courses (< 5 days) are only for those meeting stability criteria (see Glossary). * **Exceptions:** Shorter courses are not recommended for severe CAP, necrotizing pneumonia (e.g., *S. aureus* or *P. aeruginosa*), or patients with underlying lung disease like bronchiectasis. ### Systemic Corticosteroids The update reflects a shift in understanding the host immune response. * **Severe CAP:** Corticosteroids are suggested to reduce mortality and length of stay. Timing is critical; early administration (within 24 hours) is preferred. * **Nonsevere CAP:** Corticosteroids are recommended against due to the risk of side effects like hyperglycemia without a proven mortality benefit. * **The Influenza Exclusion:** Corticosteroids are specifically excluded for patients with influenza pneumonia due to observational data suggesting potential harm. --- ## Short-Answer Practice Questions 1. **What are the two "major criteria" used to define severe community-acquired pneumonia?** * *Answer:* Septic shock requiring vasopressors and respiratory failure requiring mechanical ventilation. 2. **Why is the recommendation for antibiotic duration conditional for outpatients?** * *Answer:* Shorter courses require individualization, close follow-up, and clear communication regarding signs of recurrence, which may be difficult in some clinical settings. 3. **What specific sonographic features should a clinician look for when using LUS to diagnose pneumonia?** * *Answer:* Consolidation (irregular marginal contour, air bronchogram), vertical artifacts (B-lines), and pleural effusion. 4. **Under what circumstances should a clinician still prescribe antibiotics to an outpatient who tests positive for a respiratory virus?** * *Answer:* When the patient has significant comorbidities, such as chronic pulmonary disease (COPD, interstitial lung disease), end-stage liver or renal disease, cardiovascular disease, alcoholism, or neoplastic disease. 5. **Why did the committee issue a strong recommendation against corticosteroids in nonsevere CAP despite "low-quality" evidence?** * *Answer:* The intent is to avoid robustly documented harmful side effects, such as hyperglycemia, in a population where there is no clear mortality benefit. 6. **What is the minimum recommended duration for a short course of antibiotics in clinically stable, nonsevere CAP?** * *Answer:* A minimum of 3 days of effective duration. --- ## Essay Prompts for Deeper Exploration 1. **The Evolution of Pneumonia Pathogenesis:** Discuss how the shift from viewing the lung as a "sterile compartment" to an "active ecosystem" (involving dysbiosis and host response) impacts the move toward individualized, shorter antibiotic treatments. 2. **Diagnostic Discrepancy and LUS:** Analyze the clinical and practical implications of using lung ultrasound as a diagnostic tool in resource-limited settings versus high-resource settings. Consider factors like radiation exposure, cost, and the necessity of ruling out alternative diagnoses. 3. **The Balancing Act of Viral-Bacterial Management:** Evaluate the challenge of "double sickening" and the lack of reliable biomarkers (like procalcitonin) in distinguishing between viral and bacterial pneumonia. Argue for or against the guideline's cautious approach to inpatient empiric therapy. 4. **Patient-Centered Care in CAP:** Using the "Patient Input" section of the guideline, explain how a clinician should navigate a management plan when the evidence is of "low quality" or "conditional." How do patient values regarding side effects and convenience influence the final decision? --- ## Glossary of Important Terms * **Alveoli:** Small air sacs in the lungs where inflammation occurs during pneumonia. * **B-lines:** Vertical artifacts visualized on lung ultrasound that can indicate lung pathology. * **Clinical Stability:** A state defined by meeting several criteria: Temperature <37.8°C, Heart Rate <100 bpm, Respiratory Rate <24 breaths/min, Systolic BP >90 mmHg, SpO2 >90% on room air, and normal mental status. * **Community-Acquired Pneumonia (CAP):** A lower respiratory tract infection (LRTI) acquired outside of hospital or healthcare settings. * **Double Sickening:** A clinical pattern where a patient begins to improve after a viral illness but then suddenly worsens, often indicating a secondary bacterial infection. * **Dysbiosis:** An imbalance in microbial populations within the lung ecosystem. * **Effective Duration:** The period during which an antibiotic remains therapeutically active in the body, which may exceed the number of days the medication is physically ingested (notably with macrolides). * **Immunocompromised Host (ICH):** Individuals with compromised immune systems due to conditions (HIV, malignancy) or treatments (chemotherapy, chronic glucocorticoids). *Note: The 2025 CAP guidelines do not apply to this population.* * **Lung Ultrasound (LUS):** A point-of-care imaging technique used at the bedside to visualize lung pathologies. * **Procalcitonin:** A biomarker often used to help distinguish between bacterial and viral infections, though its sensitivity and specificity in CAP are approximately 75–80%.